Molecular physiology of platelet ADP receptors

Drug Development Research

Volumn 45, Issue 3-4, 1998, Pages 135-139

  Kunapuli, Satya P ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ADP receptor; P2 receptors; P2T receptor; P2Y1 receptor; Platelet aggregation; Platelets

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; CELL SURFACE RECEPTOR; FIBRINOGEN RECEPTOR; NUCLEOTIDE; PURINE P2 RECEPTOR; PURINE P2T RECEPTOR; PURINE P2X RECEPTOR; PURINE P2Y RECEPTOR; THROMBOCYTE RECEPTOR; UNCLASSIFIED DRUG;

BLOOD VESSEL INJURY; CONFERENCE PAPER; MOLECULAR CLONING; MOLECULAR DYNAMICS; RECEPTOR INTRINSIC ACTIVITY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE SHAPE;

EID: 0032453131     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199811/12)45:3/4<135::AID-DDR8>3.0.CO;2-B     Document Type: Conference Paper

References (46)

1. Bom GVR. 1962. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194:927-929.
2. Boyer JL, Romeroavila T, Schachter JB, Harden TK. 1996. Identification of competitive antagonists of the P2Y(1) receptor. Mol Pharmacol 50:1323-1329.
3. Cattaneo M, Lecchi A, Randi AM, McGregor JL, Mannucci FM. 1992. Identification of a new congenital defect of platelet aggregation characterized by severe impairment of platelet responses to adenosine 5′-diphosphate. Blood 80:2787-2796.
4. Cusack NJ, Hourani SMO. 1982. Adenosine diphosphate antagonists and human platelets: no evidence that aggregation and inhibition of adenylate cyclase are mediated by different receptors. Br J Pharmacol 76:221-227.
5. Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SE 1998. Molecular basis for ADP-induced platelet activation I: evidence for three distinct ADP receptors on platelets. J Biol Chem 273:2024-2029.
6. Defreyn G, Cachet G, Savi P, Driot F, Cazenave J-P, Maffrand J-E1991. Ticlopidine and Clopidogrel (SR25990C) selectively neutralize ADP inhibition of PGEi-activated platelet adenylate cyclase in rats and rabbits. Thromb Haemost 65:186-190.
7. Fagura MS, Dainty IA, McKay GD, Kirk IP, Humphries RG, Robertson MJ, Dougall IG, Leff E 1998. P2Y(l)-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors. Br J Pharmacol 124:157-164.
8. Fredholm BB, Abbracchio ME Bumstock G, Dubyak GR, Harden TK, Jacobson KA, Schwabe U, Williams M. 1997. Towards a revised nomenclature for PI and P2 receptors. Trends Pharmacol Sei 18:79-82.
9. Gaarder A, Jonsen A, Laland S, Hellem AJ, Owren E 19G1. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 192:531-532.
10. 1. Biochem Pharmacol 40:2683-2687.
11. Cachet C, Cattaneo M, Ohlmann P, Hechler B, Lecchi A, Chervalier J, Cassel D, Mannucci PM, Cazenave J-E 1995. Purinoceplors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol 91: 434-144.
12. Cachet C, Hechler B, Leon C, Vial C, Leray C, Ohlmann E Cazenave JE 1997. Activation of AD P receptors and platelet function. Thromb Haemost 77:271-275.
13. Geiger J, Honigliedl F, Schanzenbacher P, Walter U. 1998. Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptors. Eur J Pharmacol 351:235-246.
14. Gordon J. 1986. Extracellular ATP: effects, sources and fates. Biochem J 233:309-319.
15. Hechler B, Leon C, Vial C, Vigne P, Freiin C, Cazenave JE Cachet C. 1998. The P2Y(1) receptor is necessary for adenosine 5′-diphosphate-induced platelet aggregation. Blood 92:152-159.
16. Hourani SMO, Cusack NJ. 1991. Pharmacological receptors on blood platelets. Pharmacol Rev 43:243-298.
17. Hourani SMO, Hall DA. 1994. Receptors for ADP on human platelets. Trends Pharmacol Sei 15:103-108.
18. 2T purinoceptor antagonists: definition of the role of ADP in arterial thrombosis. Trends Pharmacol Sei 16:179-181.
19. Jantsen H-M, Gousset L, Bhaskar V, Vincent D, Tai A, Reynolds E, Conley PD. 1998. Evidence for a platelet ADP receptor mediating platelet activation distinct from P2Y1. Drug Dev Res 43:6 (abstract).
20. Jin J, Kunapuli SE 1998. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sei USA 95:8070-8074.
21. Jin J, Daniel JL, Kunapuli SE 199S. Molecular basis for ADP-induced platelet activation. II: the P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 273:2030-2034.
22. Kaplan KL, Broekman MJ, Chemoff A, Lesznik GR, Drillings M. 1979. Platelet α-granule proteins: studies on release and subcellular localization. Blood 53:604-618.
23. Kunapuli SE 1998. Multiple P2 receptor subtypes on platelets: a new interpretation of their function. Trends Phannacol Sei 19:391-394.
24. Leon C, Hechler B, Vial C, Leray C, Cazenave JE Cachet C. 1997. The P2Y(1) receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEES Lett 403:26-30.
25. Macfarlane DE. 1987. Agonists and receptors: adenosine diphosphate. In: Holmsen H, editor. Platelet responses and metabolism. Vol II: receptors and metabolism. Boca Raton: CRC Press, p 19-36.
26. Macfarlane DE, Mills DCB. 1975. The effects of ATP on platelets: evidence against the central role of ADP in primary aggregation. Blood 46:309-320.
27. 32P]diphosphate to the receptor on intact human blood platelets which inhibits adenylate cyclase. Biochemistry 21:544-549.
28. 32P]diphosphate: an agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood platelets. J Clin Invest 71:420-428.
29. 2T purinoceptors in human platelets. J Biol Chem 271:2879-2881.
30. Mills DCB. 199G. ADP receptor in platelets. Thromb Haemost 76:835-856.
31. Mills DCB, Robb IA, Roberts GCK. 1968. The release of nucleotides, 5-hydroxytiyptamine and enzymes from human blood platelets during aggregation. J Physiol 193:715-729.
32. Mills DCB, Figures WR, Scearce LM, Stewart GJ, Colman RE Colman R\V. 1985. Two mechanisms for inhibition of ADP-induced platelet shape change by 5'-p-fluorosulfonylbenzoyI adenosine: conversion to adenosine and covalent modification at an ADP binding site distinct from that which inhibits adenylate cyclase. J Biol Chem 260:8078-8083.
33. Mills DCB, Puri RN, Hu C-J, Minnitti C, Grana G, Freedman M, Colman RF, Colman RW. 1992. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Atheroscler Thromb 12:430-136.
34. Mustard JF, Perry DW, Kinlough-Rathbone RL, Packham MA. 1975. Factors responsible for ADP induced release reaction of human platelets. Am J Physiol 228:1857-1865.
35. Nurden P, Savi P, Heilmann E, Bihour C, Herbert J-M, Maffrand J-P, Nurden A. 1995. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. J Clin Invest 95:1612-1622.
36. αq-deficient mice. Nature 389:183-186.
37. Packliam MA, Bryant ML, Guccione MA, Kinlough-Rathbone RL, Mustard JE 1989. Effect of concentration of Ca+2 in the suspending medium on the responses of human and rabbit platelets to aggregating agents. Thromb Haemost 62:968-976.
38. Pengo y Boschello A, Marzari A, Baca M, Schivazappa L, Dalla Volta S. 1986. Adenosine diphosphate (ADP)-induced a-granules release from platelets of native whole blood is reduced by ticlopidine but not by aspirin or dipyridamole. Thromb Haemost 56:147-150.
39. Puri RN, Colman RW. 1997. ADP-induced platelet activation. Crit Rev Biochem Mol Biol 3:437-502.
40. Rand ML, Perry DW, Packliam MA, Gemmell CH, Yeo EL, KinlougliRathbone RL. 1996. Conditions influencing release of granule contents from human platelets in citraled plasma induced by ADP or the thrombin receptor activating peptide SFLLRN: direct measurement of percent release of β-thromboglobulin and assessment by flow cytometry of P-selectin expression. Am J Hematol 52:288-294.
41. Rao AK, Kowalska MA. 1987. ADP-induced platelet shape change and mobilization of cytoplasmic ionized calcium are mediated by distinct binding sites on platelets: 5′-p-fluorosulfonylbenzoyladenosine is a weak platelet agonist. Blood 70:751-756.
42. Rao AK, Koike K, Willis J, Daniel JL, Beckett C, Kassel B, Day HJ, Smith JB, Holmsen H. 1984. Platelet secretion defect associated with impaired liberation of arachidonic acid and normal myosin light chain phosphorylation. Blood 64:914-921.
43. Rinder CS, Student LA, Bonan JL, Rinder HM, Smith BR. 1993. Aspirin does not inhibit adenosine diphosphate-induced platelet α-granule release. Blood 82:505-512.
44. Savi P, Bornia J, Salel V, Delfaud M, Herbert JM. 1997. Characterization of P2X1 purinoreceptors on rat platelets: effect of Clopidogrel. Br J Haematol 98:880-886.
45. Savi P, Beauverger P, Labouret C, Delfaud M, Salel V, Kaghad M, Herbert JM. 1998. Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS Lett 422:291-295.
46. Schachter JB, LiQ, Boyer JL, Nicholas RA, Harden TK. 1996. Second messenger cascade specificity and pharmacological selectivity of the human P2Yl-purinoceptor. Br J Pharmacol 118:167-173.